Insider Selling: Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Sells 10,738 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Faith L. Charles sold 10,738 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $62,924.68. Following the completion of the sale, the director directly owned 139,094 shares of the company's stock, valued at approximately $815,090.84. This represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Abeona Therapeutics Trading Down 1.9%

Shares of NASDAQ:ABEO traded down $0.11 during mid-day trading on Friday, hitting $5.74. The stock had a trading volume of 774,254 shares, compared to its average volume of 701,588. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.90. The company has a market cap of $293.64 million, a PE ratio of -4.52 and a beta of 1.51. Abeona Therapeutics Inc. has a 12-month low of $3.93 and a 12-month high of $7.32. The company's 50 day moving average is $6.01 and its 200-day moving average is $5.57.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. On average, sell-side analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its stake in Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company's stock valued at $954,000 after buying an additional 66,422 shares during the period. Newtyn Management LLC increased its stake in Abeona Therapeutics by 26.3% in the 1st quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock valued at $2,285,000 after buying an additional 100,000 shares during the period. Trexquant Investment LP increased its stake in shares of Abeona Therapeutics by 74.1% during the 1st quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company's stock worth $568,000 after purchasing an additional 50,758 shares during the last quarter. OMERS ADMINISTRATION Corp increased its stake in shares of Abeona Therapeutics by 11.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after purchasing an additional 7,155 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Abeona Therapeutics by 64.1% during the 1st quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company's stock worth $729,000 after purchasing an additional 59,832 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ABEO shares. HC Wainwright upped their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $19.00 target price for the company. Stifel Nicolaus cut their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a research note on Thursday, May 15th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Abeona Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $19.25.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.